By 2027, the global market for aseptic processing is expected to reach USD 12.5 billion. This demand has been largely driven by the increased demand for parenteral drugs, which require strict sterility procedures. Because parenteral drugs are injected directly into the bloodstream, they bypass many of the body’s natural defenses. This means that any contaminants present in the formulation can cause serious issues in aseptic processing during the manufacturing process.
So, how can pharmaceutical manufacturers work with parenteral products to ensure careful handling?